ArticleFrontiers in immunology2026
Impact of donor stress-induced hyperglycemia on early graft outcomes in simultaneous pancreas-kidney transplantation: a retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The suitability of donors with stress-induced hyperglycemia (SIH) for pancreas-containing transplants remains debated due to concerns over β-cell dysfunction. This study aimed to assess whether donor SIH is associated with early clinical graft outcomes, including metabolic recovery, complications, and graft/patient survival, following simultaneous pancreas-kidney transplantation (SPKT). Methods: In this retrospective cohort study, 251 SPKT recipients were stratified into two groups based on donor glycemic status during ICU stay: Normoglycemia (NG, n=41; all glucose measurements ≤11.1 mmol/L without insulin therapy) and SIH (n=210; sustained glucose >11.1 mmol/L requiring intravenous insulin infusion). Recipient demographics, postoperative pancreatic/renal graft function, complications, and long-term survival were compared between groups. Results: Donor and recipient baseline characteristics were comparable between groups, except for higher admission glucose in the SIH cohort. Postoperatively, no significant differences were observed between the SIH and NG groups in serial measurements of fasting glucose, HbA1c, C-peptide, serum amylase, or serum creatinine at 7 days, 1, 6, and 12 months (all p>0.05). Complication rates, including delayed graft function, acute rejection, graft thrombosis, and surgical fistulas, were also similar (all p>0.05). Most importantly, Kaplan-Meier analysis revealed no significant differences in death-censored pancreas or kidney graft survival, or in overall patient survival over the follow-up period (maximum 9.2 years) (all log-rank p>0.05). Conclusion: In this single-center, retrospective cohort with limited statistical power, we did not detect a statistically significant association between donor SIH and adverse early metabolic recovery, complication rates, or long-term graft and patient survival following SPKT. These observational data do not establish equivalence. The study is underpowered for uncommon events such as graft thrombosis, and clinically meaningful differences cannot be excluded. The findings should be interpreted as hypothesis-generating. They require prospective validation in larger, multi-center cohorts before informing clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.